Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men
HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population. Anal specimens were collected from HIV-infected MSM attend...
Saved in:
| Published in | Future microbiology Vol. 13; no. 13; pp. 1463 - 1472 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Future Medicine Ltd
01.10.2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1746-0913 1746-0921 1746-0921 |
| DOI | 10.2217/fmb-2018-0149 |
Cover
Loading…
| Abstract | HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.
Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.
A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.
A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated. |
|---|---|
| AbstractList | HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.
Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.
A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.
A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated. HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.AIMHIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population.Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.MATERIALS & METHODSAnal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test.A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.RESULTSA total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes.A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated.CONCLUSIONA substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated. HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population. Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test. A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes. A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated. Aim: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV vaccine (4vHPV) and nonavalent HPV vaccine (9vHPV) was estimated in this population. Materials & methods: Anal specimens were collected from HIV-infected MSM attending a sexually transmitted infection/HIV center. Specimens were analyzed using the Linear Array HPV Genotyping Test. Results: A total of 49.5 and 71.2% of the 313 enrolled MSM harbored at least one of the 4vHPV and 9vHPV types, respectively. A significantly decreasing trend was observed for the prevalence of both 4vHPV (p = 0.04) and 9vHPV types (p < 0.001) across age classes. Conclusion: A substantial proportion of HIV-infected MSM do not harbor a current anal infection with vaccine-preventable HPVs. The potential benefit of the 4vHPV versus 9vHPV vaccination in these subjects, including older MSM, should be investigated. |
| Author | Moretto, Domenico Giuliani, Massimo Giglio, Amalia Rollo, Francesca Latini, Alessandra Cristaudo, Antonio Zaccarelli, Mauro Giuliani, Eugenia Benevolo, Maria Rezza, Giovanni Colafigli, Manuela Donà, Maria G |
| AuthorAffiliation | 2Pathology Department, Regina Elena National Cancer Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy 4Department of Molecular Medicine, Sapienza University, Viale Regina Elena, 291-293 00161, Rome, Italy 6Department of Infectious, Parasitic & Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00141, Rome, Italy 3Clinical and Research Department, Istituto Nazionale Malattie Infettive INMI Lazzaro Spallanzani IRCCS, Via Portuense, 292, 00149, Rome, Italy 1HIV/STI Unit, Clinical and Experimental Dermatology Department, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy 5Microbiology & Clinical Pathology Department, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy |
| AuthorAffiliation_xml | – name: 5Microbiology & Clinical Pathology Department, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy – name: 3Clinical and Research Department, Istituto Nazionale Malattie Infettive INMI Lazzaro Spallanzani IRCCS, Via Portuense, 292, 00149, Rome, Italy – name: 1HIV/STI Unit, Clinical and Experimental Dermatology Department, San Gallicano Dermatological Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy – name: 4Department of Molecular Medicine, Sapienza University, Viale Regina Elena, 291-293 00161, Rome, Italy – name: 6Department of Infectious, Parasitic & Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00141, Rome, Italy – name: 2Pathology Department, Regina Elena National Cancer Institute IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy |
| Author_xml | – sequence: 1 givenname: Massimo surname: Giuliani fullname: Giuliani, Massimo – sequence: 2 givenname: Alessandra surname: Latini fullname: Latini, Alessandra – sequence: 3 givenname: Manuela surname: Colafigli fullname: Colafigli, Manuela – sequence: 4 givenname: Maria surname: Benevolo fullname: Benevolo, Maria – sequence: 5 givenname: Francesca surname: Rollo fullname: Rollo, Francesca – sequence: 6 givenname: Mauro surname: Zaccarelli fullname: Zaccarelli, Mauro – sequence: 7 givenname: Eugenia surname: Giuliani fullname: Giuliani, Eugenia – sequence: 8 givenname: Domenico surname: Moretto fullname: Moretto, Domenico – sequence: 9 givenname: Amalia surname: Giglio fullname: Giglio, Amalia – sequence: 10 givenname: Giovanni surname: Rezza fullname: Rezza, Giovanni – sequence: 11 givenname: Antonio surname: Cristaudo fullname: Cristaudo, Antonio – sequence: 12 givenname: Maria G surname: Donà fullname: Donà, Maria G |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30311788$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kU1v3CAQhlGVqvk89loh9dILCQPexRyrqG0iRcolzRVhdqiJbHDB3iT_vrac9BApJ4bR845gnmNyEFNEQj4DPxcC1IXvGyY41IxDpT-QI1DVlnEt4OB_DfKQHJfywPmmBg2fyKHkEkDV9RFp761zISIbMu4xjrbpkNpoOxqiRzeGFAttnmk79TbSwQ6h61Jv9yFPhdo-xT_06vqerTDuaI-RPraJtnaPtOATfQxju3RPyUdvu4JnL-cJ-f3zx93lFbu5_XV9-f2GOalgZHbjtaiVrhxI4KAroZHzhkvvudo5uUWlN7VSXuy8UxtnNWpQ6HgtK-XEVp6Qb-vcIae_E5bR9KE47DobMU3FCAA9J5TUM_r1DfqQpjz_faakqGuupV6oLy_U1PS4M0MOvc3P5nWHMyBXwOVUSkZvXBjtsrkx29AZ4GYxZWZTZjFlFlNzir1JvQ5-j9cr76dxylhcwOjQrLf5XWGx-E72HxRip4I |
| CitedBy_id | crossref_primary_10_1093_cid_ciaa002 crossref_primary_10_1097_LGT_0000000000000763 crossref_primary_10_1002_rmv_2219 |
| Cites_doi | 10.1086/656775 10.1136/sextrans-2015-052032 10.1097/QAI.0b013e3182a7acd2 10.1093/infdis/jix607 10.1002/ijc.28963 10.1016/j.cmi.2016.08.011 10.1097/QAI.0000000000000855 10.1158/1055-9965.EPI-13-0460 10.1016/j.jcv.2012.02.014 10.1200/JCO.2017.72.5465 10.1002/cncr.23744 10.1128/JCM.00620-08 10.1016/j.vaccine.2011.01.015 10.1038/sj.bjc.6603175 10.1056/NEJMoa1010971 10.1128/JCM.01405-13 10.1093/cid/ciw845 10.1016/j.vaccine.2017.08.006 10.1016/j.jinf.2015.02.001 10.1038/bjc.2015.90 10.1186/s13027-017-0129-6 10.1016/S1473-3099(14)70994-6 10.1002/jmv.21732 10.7448/IAS.17.4.19662 10.1016/j.vaccine.2012.04.105 10.2217/fmb.14.44 10.1186/s12981-017-0160-0 10.1002/ijc.28431 10.1097/QAD.0000000000001354 10.1097/MD.0000000000008109 10.1002/jmv.24943 10.1128/JCM.00517-06 10.1093/jnci/djs371 10.1016/j.jcv.2015.09.001 10.1097/QAD.0000000000000909 10.1016/j.pvr.2017.02.003 10.1002/ijc.26115 10.1016/S1470-2045(12)70080-3 10.1002/jmv.24406 10.1097/OLQ.0000000000000372 10.1097/OLQ.0000000000000244 10.1093/cid/cir1012 10.1056/NEJMoa0909537 10.1016/S1473-3099(17)30653-9 10.1097/QAD.0000000000001045 |
| ContentType | Journal Article |
| Copyright | 2018 Future Medicine Ltd Copyright Future Medicine Ltd Oct 2018 |
| Copyright_xml | – notice: 2018 Future Medicine Ltd – notice: Copyright Future Medicine Ltd Oct 2018 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO EHMNL FYUFA GHDGH GNUQQ HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI 7X8 |
| DOI | 10.2217/fmb-2018-0149 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central UK & Ireland Database (ProQuest) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library UK & Ireland Database ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: Proquest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1746-0921 |
| EndPage | 1472 |
| ExternalDocumentID | 30311788 10_2217_fmb_2018_0149 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | - 0R 29H 3V. 53G 5GY 70G 7RV 7X7 88E 8AO 8C1 8CJ 8FE 8FH 8FI 8FJ ABUWG ACGFS ACPRK AENEX AFKRA AHMBA ALMA_UNASSIGNED_HOLDINGS BBAFP BBNVY BENPR BHPHI BKEYQ BPHCQ BVXVI CS3 D1J DU5 EBS EHMNL EJD F5P FYUFA H13 HCIFZ HZ IAO IEA IHR LK8 M1P M7P MV1 NTCAX O9- P2P PQQKQ PRINS PSQYO RFM --- 0R~ 0VX 4.4 AAWFG AAYXX ABJNI ACWKX ADBBV AFFYO ALIPV CCPQU CITATION HMCUK HZ~ ITC M4Z NAPCQ OVD PHGZM PHGZT PROAC RPM TDBHL TEORI TFL TFMDE TMEDX UKHRP CGR CUY CVF ECM EIF NPM 7XB 8FK ABNDM AZQEC DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI 7X8 |
| ID | FETCH-LOGICAL-c371t-a5f928794c131019429e00b03ff07dc36e795877f2dfc75ca9e917ec08347c263 |
| IEDL.DBID | 7X7 |
| ISSN | 1746-0913 1746-0921 |
| IngestDate | Thu Aug 07 14:58:26 EDT 2025 Fri Jul 25 19:15:24 EDT 2025 Thu Jan 02 23:01:45 EST 2025 Thu Apr 24 23:11:12 EDT 2025 Tue Jul 01 05:15:07 EDT 2025 Tue Jan 05 21:37:51 EST 2021 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | vaccine HIV anal MSM HPV |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c371t-a5f928794c131019429e00b03ff07dc36e795877f2dfc75ca9e917ec08347c263 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 30311788 |
| PQID | 2328809399 |
| PQPubID | 54596 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2119917739 proquest_journals_2328809399 pubmed_primary_30311788 crossref_citationtrail_10_2217_fmb_2018_0149 crossref_primary_10_2217_fmb_2018_0149 futurescience_futuremedicine_10_2217_fmb_2018_0149 |
| ProviderPackageCode | RFM NTCAX 70G CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-October-01 2018-10-00 20181001 |
| PublicationDateYYYYMMDD | 2018-10-01 |
| PublicationDate_xml | – month: 10 year: 2018 text: 2018-October-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Future microbiology |
| PublicationTitleAlternate | Future Microbiol |
| PublicationYear | 2018 |
| Publisher | Future Medicine Ltd |
| Publisher_xml | – name: Future Medicine Ltd |
| References | e_1_3_5_29_1 e_1_3_5_28_1 e_1_3_5_27_1 e_1_3_5_26_1 e_1_3_5_25_1 e_1_3_5_24_1 e_1_3_5_23_1 e_1_3_5_22_1 e_1_3_5_44_1 e_1_3_5_45_1 e_1_3_5_46_1 e_1_3_5_47_1 e_1_3_5_48_1 e_1_3_5_49_1 e_1_3_5_3_1 e_1_3_5_40_1 e_1_3_5_41_1 e_1_3_5_42_1 e_1_3_5_43_1 e_1_3_5_9_1 e_1_3_5_21_1 e_1_3_5_8_1 e_1_3_5_20_1 e_1_3_5_5_1 e_1_3_5_4_1 e_1_3_5_7_1 e_1_3_5_6_1 e_1_3_5_18_1 e_1_3_5_17_1 e_1_3_5_39_1 e_1_3_5_16_1 e_1_3_5_38_1 e_1_3_5_15_1 e_1_3_5_37_1 e_1_3_5_13_1 e_1_3_5_14_1 e_1_3_5_36_1 e_1_3_5_35_1 e_1_3_5_11_1 e_1_3_5_34_1 e_1_3_5_12_1 e_1_3_5_33_1 e_1_3_5_19_1 e_1_3_5_50_1 e_1_3_5_32_1 e_1_3_5_10_1 e_1_3_5_31_1 e_1_3_5_30_1 |
| References_xml | – ident: e_1_3_5_5_1 doi: 10.1086/656775 – ident: e_1_3_5_24_1 doi: 10.1136/sextrans-2015-052032 – ident: e_1_3_5_42_1 doi: 10.1097/QAI.0b013e3182a7acd2 – ident: e_1_3_5_47_1 doi: 10.1093/infdis/jix607 – ident: e_1_3_5_48_1 doi: 10.1002/ijc.28963 – ident: e_1_3_5_32_1 doi: 10.1016/j.cmi.2016.08.011 – ident: e_1_3_5_40_1 doi: 10.1097/QAI.0000000000000855 – ident: e_1_3_5_45_1 doi: 10.1158/1055-9965.EPI-13-0460 – ident: e_1_3_5_31_1 doi: 10.1016/j.jcv.2012.02.014 – ident: e_1_3_5_14_1 doi: 10.1200/JCO.2017.72.5465 – ident: e_1_3_5_16_1 doi: 10.1002/cncr.23744 – ident: e_1_3_5_36_1 doi: 10.1128/JCM.00620-08 – ident: e_1_3_5_17_1 doi: 10.1016/j.vaccine.2011.01.015 – ident: e_1_3_5_15_1 doi: 10.1038/sj.bjc.6603175 – ident: e_1_3_5_21_1 doi: 10.1056/NEJMoa1010971 – ident: e_1_3_5_39_1 doi: 10.1128/JCM.01405-13 – ident: e_1_3_5_25_1 doi: 10.1093/cid/ciw845 – ident: e_1_3_5_27_1 doi: 10.1016/j.vaccine.2017.08.006 – ident: e_1_3_5_4_1 doi: 10.1016/j.jinf.2015.02.001 – ident: e_1_3_5_33_1 doi: 10.1038/bjc.2015.90 – ident: e_1_3_5_3_1 doi: 10.1186/s13027-017-0129-6 – ident: e_1_3_5_50_1 doi: 10.1016/S1473-3099(14)70994-6 – ident: e_1_3_5_6_1 doi: 10.1002/jmv.21732 – ident: e_1_3_5_30_1 doi: 10.7448/IAS.17.4.19662 – ident: e_1_3_5_37_1 doi: 10.1016/j.vaccine.2012.04.105 – ident: e_1_3_5_23_1 doi: 10.2217/fmb.14.44 – ident: e_1_3_5_22_1 doi: 10.1186/s12981-017-0160-0 – ident: e_1_3_5_12_1 doi: 10.1002/ijc.28431 – ident: e_1_3_5_44_1 doi: 10.1097/QAD.0000000000001354 – ident: e_1_3_5_46_1 doi: 10.1097/MD.0000000000008109 – ident: e_1_3_5_8_1 doi: 10.1002/jmv.24943 – ident: e_1_3_5_35_1 doi: 10.1128/JCM.00517-06 – ident: e_1_3_5_26_1 – ident: e_1_3_5_19_1 doi: 10.1093/jnci/djs371 – ident: e_1_3_5_29_1 – ident: e_1_3_5_34_1 doi: 10.1016/j.jcv.2015.09.001 – ident: e_1_3_5_11_1 doi: 10.1097/QAD.0000000000000909 – ident: e_1_3_5_38_1 doi: 10.1016/j.pvr.2017.02.003 – ident: e_1_3_5_18_1 doi: 10.1002/ijc.26115 – ident: e_1_3_5_10_1 doi: 10.1016/S1470-2045(12)70080-3 – ident: e_1_3_5_9_1 doi: 10.1002/jmv.24406 – ident: e_1_3_5_28_1 – ident: e_1_3_5_41_1 doi: 10.1097/OLQ.0000000000000372 – ident: e_1_3_5_43_1 doi: 10.1097/OLQ.0000000000000244 – ident: e_1_3_5_13_1 doi: 10.1093/cid/cir1012 – ident: e_1_3_5_20_1 doi: 10.1056/NEJMoa0909537 – ident: e_1_3_5_49_1 doi: 10.1016/S1473-3099(17)30653-9 – ident: e_1_3_5_7_1 doi: 10.1097/QAD.0000000000001045 |
| SSID | ssj0058191 |
| Score | 2.2028854 |
| Snippet | HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent HPV... Aim: HIV-infected men who have sex with men (MSM) show the highest prevalence of anal HPV infection. Anal prevalence of the HPVs targeted by the quadrivalent... |
| SourceID | proquest pubmed crossref futurescience |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1463 |
| SubjectTerms | Adult Age groups anal Anal Canal - virology Anus Diseases - diagnosis Anus Diseases - epidemiology Anus Diseases - prevention & control Anus Diseases - virology Cancer Cohort Studies Deoxyribonucleic acid Disease DNA Drug therapy Enrollments Family medical history Gays & lesbians Genotyping HIV HIV - genetics HIV - immunology HIV Infections - diagnosis HIV Infections - epidemiology HIV Infections - virology Homosexuality, Male HPV Human immunodeficiency virus Human papillomavirus Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology Humans Immunization Immunology Incidence Infections Male Males Mens health MSM Papillomaviridae - genetics Papillomaviridae - immunology Papillomavirus Infections - diagnosis Papillomavirus Infections - epidemiology Papillomavirus Infections - prevention & control Papillomavirus Infections - virology Population Prevalence Prospective Studies Sexually Transmitted Diseases - diagnosis Sexually Transmitted Diseases - epidemiology Sexually Transmitted Diseases - prevention & control Sexually Transmitted Diseases - virology Vaccination vaccine Vaccines Warts |
| Title | Vaccine-preventable anal infections by human papillomavirus among HIV-infected men who have sex with men |
| URI | http://dx.doi.org/10.2217/fmb-2018-0149 https://www.ncbi.nlm.nih.gov/pubmed/30311788 https://www.proquest.com/docview/2328809399 https://www.proquest.com/docview/2119917739 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96ByKI-HmunksE8clg0zSb5kn0uGMV7hDxjn0rSZqwB3ttve6e-t8706SrPqwvpR_TUmYmmflNJjOEvM5DoWuAO8w5V7NCusB0EIJJZ0UdlBHa4m7k07PZ_Lz4vJCLFHDrU1rlOCcOE3XdOoyRvwPLD6qmwZ6-774z7BqFq6uphcZtso-lyxB8qcUWcEkEI3FDJKBmzUWssZmDFw5Ss6AgHBO5sIzmXzbpXizmkQzQbsdzMEAnD8j95DnSD1HUD8kt3zwid07T2vhjsrwwDs9YF6sy4Z4oavCVMeGq6an9RYeufLQz3eVq1V6Zm8vrTU-HnkN0_umCRWJf0yvf0B_Lli7Njae9_0kxZIt3n5Dzk-NvR3OW-igwJxRfMyODBmCkC8fBmeMaTJDPMpuJEDJVOzHzSstSqZDXwSnpjPYA4rwD76xQLp-Jp2SvaRv_jFCpa2dDiZW7wPwZAxjUyWDrsjA2ZMJOyNuRk5VLRcax18WqArCBjIexYytkfIWMn5A3W_IuVtfYRZj_I5YqXo35B7teOhxlV6WR2Vd_9GhCXm0fw5jChRLT-HYDNBwTwpQSQHMQZb79PTD5nKuyfP7_j78gdwf1GtL-Dsne-nrjX4L7srbTQUfhWB7xKdn_eHz25et0iDL9BpaA8fQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwzV1Lb9QwEB6VVgIkxJuyUMBIwAmXJE7W8YEDglZZuruntuot2I6trbpNVs1uS_kr_BV-HOM4WR7ScqvELY-xlcfnmfmSz2OAV5GNRYF0h2qtCxon2lJhGaOJVqywXDKh3Gzk0bifHcSfj5KjNfjezYVxssrOJzaOuqi0-0b-DiM_Qk1gPG0VlHvm8gL5Wf1-8Alf5uso2t3Z_5jRdgkBqhkP51QmViAnELEOMY9Bwh4JEwQqYNYGvNCsb7hIUs5tVFjNEy2FQf5iNCYmMddRn2G_12Aj5SzCIbOxk43Gw87RJ47r-PmWSMpFyHwJzwiTfASFQvyFTifmqnT-FvJu-VohbXxbndc28W33DvzonoyXtZxsL-ZqW3_7q2jkf_ro7sLtNq8mH_xAuAdrprwP10etcuABTA6ldlt05mtWuRljRLomnRytrIm6JM2ahWQmZ8fTaXUqz4_PFjVpVmQi2eCQemNTkFNTkotJRSby3JDafCXug7Y7-hAOruQ-H8F6WZXmMZBEFFrZ1NU1w-RASmToOrGqSGOpbMBUD952QMh1W4LdrQQyzZGKOdygZ1G5w03ucNODN0vzma89ssow-gNVud_r1BmrGm11aMlbv1Xnv6DSg5fL0-hx3G8kWZpqgTahk8txztBm00N2eXmYEIUhT9Mn_-78BdzI9kfDfDgY7z2Fm81IaQSSW7A-P1uYZ5jozdXzdsAR-HLVQP0JUpxecg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSokhHiWhRaMBJywmsTJOj4gVFFWu5RWHGi1t-CnttI2Cc1uS_8av46ZOFngsNx6y2McReMZz3z2PAh5nfhUWoA7zBhjWZoZz6TnnGVGc-uF4lJjNvLR8XB8kn6eZtMN8qvPhcGwyn5NbBdqWxncI98Dyw-iJsGe7vkuLOLrwehD_YNhByk8ae3baQQROXTXVwDfmveTA5jrN0ky-vTt45h1HQaY4SJeMJV5CZBBpiYGNwfwfCJdFOmIex8Ja_jQCZnlQvjEeiMyo6QDeOMM-C2pMMmQw3dvkduCg9kEXRLTFdjLEAiFZExA7DLmob5nAggAJEaDcMYYRIYlPP-yh3dDIZHO-K13elvjN7pP7nVeK90PYvaAbLjyIdk66s7lH5HZqTJ4xepQEQrzsajCIX2wV9lQfU3bjoC0VvXZfF6dq8uzi2VD235HdDw5ZYHYWXruSno1q-hMXTrauJ8Ut4vx6WNyciMcfkI2y6p0TwnNpDXa51g1DEyvUoB_Tea1zVOlfcT1gLzrOVmYrsA59tmYFwB0kPGgt7pAxhfI-AF5uyKvQ2WPdYTJP9NShLs-9mHdoJ1-7opuVWiKPzI8IK9Wr0Gf8ZBGla5aAk2MwWhCcKDZDnO--j1wN-JY5Pmz_3_8JdkC1Si-TI4Pn5M7raS10Yc7ZHNxsXS74EUt9ItWXCn5ftP68RsReC4R |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccine-preventable+anal+infections+by+human+papillomavirus+among+HIV-infected+men+who+have+sex+with+men&rft.jtitle=Future+microbiology&rft.au=Giuliani%2C+Massimo&rft.au=Latini%2C+Alessandra&rft.au=Colafigli%2C+Manuela&rft.au=Benevolo%2C+Maria&rft.date=2018-10-01&rft.pub=Future+Medicine+Ltd&rft.issn=1746-0913&rft.eissn=1746-0921&rft.volume=13&rft.issue=13&rft.spage=1463&rft_id=info:doi/10.2217%2Ffmb-2018-0149&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1746-0913&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1746-0913&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1746-0913&client=summon |